|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:FDA
2018-05-17
|
|
gptkbp:brand
|
gptkb:Aimovig
|
|
gptkbp:chemical_formula
|
C_62 H_88 N_16 O_16 S_2
|
|
gptkbp:class
|
CGRP inhibitors
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE-1
gptkb:EVOLVE-2
Phase III
ARISE
|
|
gptkbp:clinical_use
|
preventive treatment
|
|
gptkbp:contraindication
|
hypersensitivity to the drug
|
|
gptkbp:developed_by
|
gptkb:Amgen
|
|
gptkbp:dosage_form
|
pre-filled syringe
|
|
gptkbp:duration
|
as needed
|
|
gptkbp:effective_date
|
gptkb:2018
|
|
gptkbp:formulation
|
solution for injection
|
|
gptkbp:frequency_of_administration
|
once monthly
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
erenumab-aooe
|
|
gptkbp:indication
|
chronic migraine
episodic migraine
|
|
gptkbp:ingredients
|
gptkb:erenumab
|
|
gptkbp:invention
|
patented
|
|
gptkbp:manufacturer
|
gptkb:Amgen_Inc.
|
|
gptkbp:marketed_as
|
gptkb:Aimovig
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
long half-life
CGRP receptor blockade
|
|
gptkbp:research_status
|
ongoing studies
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
dizziness
fatigue
headache
nausea
insomnia
constipation
dry mouth
weight gain
injection site reactions
muscle spasms
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:calcitonin_gene-related_peptide_(CGRP)
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:weight
|
1430.6 g/mol
|
|
gptkbp:bfsParent
|
gptkb:erenumab
|
|
gptkbp:bfsLayer
|
6
|